Abstract: The invention relates to a crystalline micronisate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.

Abstract: The invention relates to powdered preparations for inhalation containing a tiotropium salt and salmeterol xinafoate, processes for preparing them and their use in the preparation of a pharmaceutical composition for treating respiratory diseases, particularly for treating COPD (chronic obstructive pulmonary disease) and asthma.

Abstract: The invention relates to a crystalline micronisate of (1 ?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.

Abstract: Powdered preparations for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a pharmaceutically acceptable salt thereof, processes for preparing them and the use thereof for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.

Abstract: The invention relates to a blister for charging an inhaler with a pharmaceutical preparation, characterised in that the blister is at least partially manufactured from a dehydrating plastics material. The invention also relates to blisters according to the invention which are filled with a pharmaceutical preparation.

Abstract: The invention relates to a process for the surface-energy passivation of lactose which is intended for use as an excipient in the production of inhalable powders, and the use of such optimised carrier materials in the manufacture of inhalable powders.

Abstract: The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.

Abstract: The present invention relates to powder formulations for inhalation containing enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3 and R4 may have the meanings given in the claims and in the specification, optionally in the form of the pharmaceutically acceptable acid addition salts thereof, as well as optionally in combination with a pharmaceutically acceptable excipient, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Abstract: An inhalable powder comprising: (a) an active substance consisting essentially of a compound of formula 1 wherein X? is a pharmaceutically acceptable anion; and (b) a physiologically acceptable excipient having an average particle size of 10 ?m to 50 ?m, processes for preparing the inhalable powder, and methods of administration for the treatment of respiratory complaints, particularly for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2-(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.

Abstract: Crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.

Abstract: The invention relates to capsules for inhalation (inhalettes) made from specific capsule materials with a reduced moisture content, which contain the active substance tiotropium in the form of powdered preparations and are characterised by increased stability.

Abstract: The invention relates to inhalable powders in the form of stable, spray-dried microparticles (embedding particles) for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a physiologically acceptable salt thereof and one or more excipients, processes for preparing such microparticles and the use thereof for preparing a powder inhalant for the treatment of headaches, migraine and cluster headache.

Abstract: A powder inhalant for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) in the form of spherically nanostructured microparticles, which are stable in their amorphous state under normal conditions (T<50° C., relative humidity <75%), a process for preparing these microparticles as well as the use thereof for preparing the powder inhalant for the treatment of headaches, migraine and cluster headache.

Abstract: The invention relates to the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof which are stable in the amorphous state under normal conditions (T<50° C., relative humidity<75%) and are in the form of microparticles, processes for preparing such microparticles from these substances and the use of these particles for preparing a pharmaceutical composition of the inhalable powder type for pulmonary and nasal inhalation, particularly for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.

Abstract: Powdered preparations for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a pharmaceutically acceptable salt thereof, processes for preparing them and the use thereof for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.

Abstract: A method of making a physically stable and homogenous powdered pharmaceutical composition comprising a tiotropium salt and a physiologically acceptable excipient, the method comprising: (a) suspending the tiotropium salt and the physiologically acceptable excipient in a suspending agent in which the tiotropium salt and the physiologically acceptable excipient are essentially insoluble to obtain a suspension; and (b) removing the suspending agent from the suspension of step (a) to obtain the pharmaceutical composition, the pharmaceutical composition itself, and method of treating respiratory diseases, especially chronic obstructive pulmonary disease and asthma, in a patient in need thereof by administering an effective amount of the pharmaceutical composition to the patient.

Abstract: Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Abstract: The invention relates to powdered preparations for inhalation containing a tiotropium salt and salmeterol xinafoate, processes for preparing them and their use in the preparation of a pharmaceutical composition for treating respiratory diseases, particularly for treating COPD (chronic obstructive pulmonary disease) and asthma.